IQVIA Hlds (IQV) Stock Forecast & Price Target

IQVIA Holdings is well positioned by its dual engine of Commercial Solutions and R&DS, with Commercial Solutions consistently meeting or beating consensus and benefiting from the 20 novel drug approvals in 3Q26, the highest since 2021, which should support commercialization spend over a multi-year horizon. On the research side, 2Q26 delivered the highest net new bookings since 2022, record NTM backlog revenue of $9.2B, and 7.5% year-over-year growth, while strong RFP flows and improving large-pharma and biotech demand point to sustained clinical outsourcing momentum. Management also sees margin expansion on track into 2H, supported by a healthier funding environment, a refocused biotech sales strategy, and an unmatched proprietary data advantage that strengthens win rates and revenue visibility.

IQVIA Holdings is exposed to execution risk because its CRO business depends on starting and completing about 3,000 clinical trials globally on time, yet 50% to 60% of trials are delayed by weak enrollment, poor site selection, or drug issues. Its scale is a strength, but also a liability, since it holds over 1.2 billion patient records, ~64 petabytes of proprietary data, and receives ~120 billion healthcare records annually, making cybersecurity or data-service disruptions potentially damaging to trust and revenue. The outlook is further pressured by government funding delays that can slow FDA reviews, talent and material sourcing constraints, FX variances, funding uncertainty, and debt-service and refinancing risk amid any slowdown in pharma spending.